About aducanumab
Anti-amyloid monoclonal antibody
Used for
- Treats Alzheimer’s disease in its early stages, including mild cognitive impairment or mild dementia.
Usual adult dose
Intravenous infusion every four weeks. Treatment starts low and increases gradually over six months; dose is based on body weight.
Common side effects
- Brain swelling or bleeding seen on MRI, sometimes without symptoms
- Headache
- Confusion or dizziness
- Falls
Important warnings
- Can cause amyloid-related imaging abnormalities (ARIA), including brain swelling or bleeding.
- MRI scans are needed before treatment and regularly during treatment.
- Risk of ARIA is higher in people with two copies of the APOE ε4 gene.
- Use is intended for early Alzheimer’s disease; clinical benefit remains uncertain.
Pregnancy
There are no adequate human pregnancy data. Potential fetal risk is unknown.
Breastfeeding
It is unknown whether aducanumab passes into breast milk or affects a nursing infant.
Interactions
- No major drug interactions are established; anticoagulants may increase concern about brain bleeding.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.